Opportunity Information: Apply for HRSA 15 078
Apply for HRSA 15 078
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Sickle Cell Disease Newborn Screening Program" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110 Maternal and Child Health Federal Consolidated Programs.
- This funding opportunity was created on Nov 25, 2014 and posted on Nov 25, 2014.
- Applicants must submit their applications by Jan 9, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,679,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,679,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification).
- As cited in 42 CFR Part 51a.3(a), any public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450(b)), is eligible to apply for this federal funding. If otherwise eligible, community and faith based organizations are eligible to apply. Awardees currently receiving funding under the SCDTDP are ineligible to receive funding under this announcement.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Sickle Cell Disease Newborn Screening Program (SCDNBSP) is a Health Resources and Services Administration (HRSA) cooperative agreement designed to strengthen how sickle cell patients and families are supported after newborn screening identifies sickle cell disease. The opportunity focuses on building and coordinating community-based follow-up services so that children and families do not fall through the cracks after diagnosis. In practical terms, the program is meant to expand counseling, education, referral to a consistent medical home, and broader support services that help patients navigate care and improve long-term health outcomes.
The central model is a national organization leading a structured, regional network of community-based organizations (CBOs). The award supports one national-level recipient with the expectation that this lead organization will have nationwide reach and will push substantial funding and responsibility out to the regions through subawards. At minimum, the lead organization is expected to establish subaward agreements with at least one sickle cell CBO in each region that can function as a regional lead. These regional leads are not only service providers; they are intended to operate as shared resources for other CBOs across their region, offering technical assistance and helping local groups strengthen outreach, education, and follow-up capacity. Where a single CBO cannot reasonably serve as the regional lead, multiple CBOs can work together in that role. If an area lacks a CBO that can carry out the expected duties, the program allows a medical center-based outreach and education program to fill that function.
The program’s goals are structured around three main outcomes. First, it aims to create a coordinated national effort to develop, implement, and maintain a strategy for identifying individuals with sickle cell disease and assessing their quality of care and outcomes, with the larger purpose of ensuring access to comprehensive care. Second, it seeks to increase the use of sickle cell educator/counselors, such as community health workers, who can serve as trusted, practical guides for patients and families. Third, it is intended to increase the number of patients who receive active care coordination, follow-up, and referral to a stable medical home. The educator/counselor role is a key operational piece: these staff are expected to educate patients and families about sickle cell disease, connect them to appropriate medical homes, and help them access community resources that influence health outcomes, including supports that go beyond the clinic.
A defining feature is that SCDNBSP is meant to align with HRSA’s existing Sickle Cell Disease Treatment Demonstration Program (SCDTDP), which also operates using a regional model. The applicant is expected to work collaboratively with SCDTDP awardees and, where applicable, with the SCDTDP Regional Collaborative within each region. This is intended to reduce duplication and create a more coherent national-to-local approach where community outreach, education, and navigation connect smoothly with clinical systems that provide ongoing treatment.
From an implementation standpoint, the national awardee is expected to function as the backbone organization for the effort. Responsibilities include serving as the lead for the national strategy, working with HRSA and CBO partners to build and maintain patient identification and outcome/quality assessment approaches, and providing technical assistance to regional and local CBOs to expand and professionalize the use of sickle cell educator/counselors. Regional CBO leads, in turn, are expected to identify additional CBOs and partners in each state within their region and coordinate activities that increase care coordination and referrals to medical homes.
Administratively, this opportunity is a discretionary HRSA cooperative agreement (Funding Opportunity Number HRSA-15-078; CFDA 93.110 Maternal and Child Health Federal Consolidated Programs). HRSA anticipated making one award, with an estimated total funding amount and ceiling of $2,679,000 and no cost sharing or matching requirement. Eligible applicants include any public or private entity as defined at 42 CFR Part 51a.3(a), including Indian tribes or tribal organizations (as defined at 25 U.S.C. 450(b)), and community- and faith-based organizations if otherwise eligible. A major eligibility restriction is that organizations currently receiving funding under the Sickle Cell Disease Treatment Demonstration Program are not eligible to receive funding under this SCDNBSP announcement. The opportunity was posted November 25, 2014, and closed January 9, 2015, with an archive date of March 10, 2015.
Overall, the grant is structured to move sickle cell follow-up beyond isolated programs and toward a coordinated national framework that still keeps services grounded in local communities. The emphasis on educator/counselors, referrals to medical homes, and measurable attention to care quality and outcomes reflects an intent to improve continuity of care starting from newborn screening and continuing through long-term disease management, with community organizations playing a central and supported role.
Frequently Asked Questions (FAQs)
What is the Sickle Cell Disease Newborn Screening Program (SCDNBSP)?
The Sickle Cell Disease Newborn Screening Program (SCDNBSP) is a Health Resources and Services Administration (HRSA) cooperative agreement designed to strengthen what happens after newborn screening identifies sickle cell disease. Its focus is on building and coordinating community-based follow-up so that children and families receive counseling, education, referrals, and ongoing support rather than falling through gaps after diagnosis.
What problem is this program trying to solve?
The program targets breakdowns that can occur after a newborn screening result indicates sickle cell disease, such as missed follow-up, inconsistent referrals, and lack of coordinated support. SCDNBSP emphasizes structured community-based follow-up services to improve continuity of care and long-term outcomes.
What kinds of services does SCDNBSP aim to expand?
Based on the description, SCDNBSP is meant to expand counseling, education, referral to a consistent medical home, and broader support services that help patients and families navigate care. It also emphasizes community resource connections that can influence health outcomes beyond clinic-based care.
How is the program structured nationally and regionally?
The model is built around one national organization that leads a structured, regional network of community-based organizations (CBOs). The national recipient is expected to have nationwide reach and to distribute substantial funding and responsibility to the regions through subawards.
How many awards did HRSA anticipate making under this opportunity?
HRSA anticipated making one award under this cooperative agreement.
What is the expected role of the national awardee?
The national awardee is expected to act as the backbone organization for the program. Responsibilities include leading the national strategy, working with HRSA and CBO partners to develop and maintain approaches for identifying individuals with sickle cell disease and assessing quality of care and outcomes, and providing technical assistance to regional and local CBOs to strengthen outreach, education, and follow-up capacity.
What are regional lead organizations expected to do?
At a minimum, the national lead organization is expected to establish subaward agreements with at least one sickle cell CBO in each region to serve as a regional lead. Regional leads are intended to be shared resources for other CBOs in their region by offering technical assistance and helping local groups strengthen outreach, education, and follow-up efforts. They are also expected to identify additional CBOs and partners in each state within their region and coordinate activities that increase care coordination and referrals to medical homes.
Does each region have to have exactly one CBO as the regional lead?
No. While the expectation is at least one sickle cell CBO per region serving as a regional lead, the opportunity states that multiple CBOs may work together as the regional lead where a single CBO cannot reasonably serve in that role.
What if a region does not have a CBO that can serve as a regional lead?
If an area lacks a CBO able to carry out the expected regional lead duties, the program allows a medical center-based outreach and education program to fill the regional lead function.
What are the main outcomes or goals of the SCDNBSP?
The opportunity describes three main outcomes:
- Creating a coordinated national effort to develop, implement, and maintain a strategy for identifying individuals with sickle cell disease and assessing quality of care and outcomes, with the purpose of ensuring access to comprehensive care.
- Increasing the use of sickle cell educator/counselors (such as community health workers) who can guide patients and families.
- Increasing the number of patients receiving active care coordination, follow-up, and referral to a stable medical home.
What is meant by "patient identification" and "assessment of quality of care and outcomes" in this program?
The program calls for a coordinated national effort to support strategies for identifying individuals with sickle cell disease and for assessing quality of care and outcomes. The stated intent is to use these approaches to help ensure access to comprehensive care, rather than leaving care connections to chance after diagnosis.
Who are "sickle cell educator/counselors" in this program?
Sickle cell educator/counselors are described as roles that may include community health workers and similar staff who serve as trusted, practical guides for patients and families. They are a key operational component of the model.
What are educator/counselors expected to do?
Educator/counselors are expected to educate patients and families about sickle cell disease, connect them to appropriate medical homes, and help them access community resources that affect health outcomes, including supports beyond the clinic.
What does "medical home" mean in the context of this opportunity?
In this opportunity, a medical home is presented as a consistent, stable place for ongoing care. A core program aim is to increase follow-up, care coordination, and referrals so more patients are connected to a stable medical home.
How does SCDNBSP relate to HRSA's Sickle Cell Disease Treatment Demonstration Program (SCDTDP)?
A defining feature of SCDNBSP is alignment with HRSA's Sickle Cell Disease Treatment Demonstration Program (SCDTDP), which also uses a regional model. The applicant is expected to collaborate with SCDTDP awardees and, where applicable, the SCDTDP Regional Collaborative within each region to reduce duplication and strengthen connections between community outreach/navigation and clinical treatment systems.
Why is collaboration with SCDTDP awardees emphasized?
The stated purpose is to reduce duplication and create a more coherent national-to-local approach, so community-based outreach, education, and navigation link smoothly with clinical systems that provide ongoing treatment.
What type of funding mechanism is SCDNBSP?
This opportunity is a discretionary HRSA cooperative agreement.
What is the Funding Opportunity Number (FON) for this announcement?
The Funding Opportunity Number listed is HRSA-15-078.
What CFDA program is associated with this opportunity?
The CFDA listed is 93.110, Maternal and Child Health Federal Consolidated Programs.
What was the estimated total funding amount and ceiling?
The opportunity states an estimated total funding amount and ceiling of $2,679,000.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
Who was eligible to apply?
Eligible applicants include any public or private entity as defined at 42 CFR Part 51a.3(a). The eligibility list also explicitly includes Indian tribes or tribal organizations (as defined at 25 U.S.C. 450(b)) and community- and faith-based organizations if otherwise eligible.
Are current Sickle Cell Disease Treatment Demonstration Program (SCDTDP) grantees eligible to apply?
No. A major eligibility restriction is that organizations currently receiving funding under the Sickle Cell Disease Treatment Demonstration Program are not eligible to receive funding under this SCDNBSP announcement.
What is the program expecting regarding subawards?
The national recipient is expected to push substantial funding and responsibility to the regions through subawards. At minimum, the lead organization is expected to establish subaward agreements with at least one sickle cell CBO in each region to function as a regional lead.
Is this opportunity still open?
No. The opportunity was posted on November 25, 2014, closed on January 9, 2015, and has an archive date of March 10, 2015.
When was the opportunity posted and when did it close?
It was posted November 25, 2014, and closed January 9, 2015. The archive date is March 10, 2015.
What is the overall intent of the program model?
The program is structured to move sickle cell follow-up beyond isolated efforts and toward a coordinated national framework that remains grounded in local communities. Emphasis is placed on educator/counselors, referrals to medical homes, active follow-up and care coordination, and measurable attention to quality of care and outcomes starting from newborn screening through long-term management.
Browse more opportunities from the same category: Health
Next opportunity: Pacific Northwest Region Water Conservation Field Services 2015 Grant Program
Previous opportunity: Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 15 078
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 15 078) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alcohol Education Project Grants (R25) Apply for PAR 15 054 Funding Number: PAR 15 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01) Apply for RFA AI 14 071 Funding Number: RFA AI 14 071 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Evaluation Capacity within the Government of Tanzania under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1589 Funding Number: CDC RFA GH15 1589 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,500,000 |
| Partnering with Pasteur Institute of Ho Chi Minh City to Enhance Regional Capacity to Prevent, Detect, Monitor, and Respond to the HIV/AIDS Epidemic in Vietnam under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1595 Funding Number: CDC RFA GH15 1595 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| Statewide Family Network Program Apply for SM 15 001 Funding Number: SM 15 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $95,000 |
| Statewide Consumer Network Program Apply for SM 15 002 Funding Number: SM 15 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $95,000 |
| Service Area Competition Additional Areas (SAC AA) Green Valley, AZ Wichita, KS Franklin, NH Washington, NC and Cheyenne, WY Apply for HRSA 15 139 Funding Number: HRSA 15 139 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics (R41) Apply for RFA HL 15 026 Funding Number: RFA HL 15 026 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics (R43/R44) Apply for RFA HL 15 027 Funding Number: RFA HL 15 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High Priority Immunology Grants (R01) Apply for PAS 15 055 Funding Number: PAS 15 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Perinatal and Infant Oral Health Quality Improvement Expansion Grant Program Apply for HRSA 15 070 Funding Number: HRSA 15 070 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Advanced Nursing Education Program Apply for HRSA 15 046 Funding Number: HRSA 15 046 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21) Apply for PA 15 057 Funding Number: PA 15 057 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Apply for PA 15 058 Funding Number: PA 15 058 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Clinical Trial or Biomarker Clinical Validation Study Cooperative Agreement (U01) Apply for PAR 15 059 Funding Number: PAR 15 059 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Predoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene Apply for HRSA 15 050 Funding Number: HRSA 15 050 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01) Apply for RFA HL 17 001 Funding Number: RFA HL 17 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events A Multicenter Program Expansion (U54) Apply for RFA CK 11 0010501SUPP15 Funding Number: RFA CK 11 0010501SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Creating Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U34) Apply for RFA HL 15 028 Funding Number: RFA HL 15 028 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Radiological/Nuclear Medical Countermeasure Product Development Program (R43/R44) Apply for PA 15 065 Funding Number: PA 15 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 15 078", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.